Cleveland BioLabs (CBLI) Competitors

Novan (NASDAQ:NOVN) and Cleveland BioLabs (NASDAQ:CBLI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Is NOVN or CBLI more profitable?

Cleveland BioLabs has a net margin of 0.00% compared to Cleveland BioLabs' net margin of -128.61%. Novan's return on equity of -32.84% beat Cleveland BioLabs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novan	-128.61%	-700.28%	-39.58%
Cleveland BioLabs	N/A	-32.84%	-31.29%

Do insiders & institutionals have more ownership in NOVN or CBLI?

14.5% of Novan shares are owned by institutional investors. Comparatively, 5.1% of Cleveland BioLabs shares are owned by institutional investors. 1.3% of Novan shares are owned by insiders. Comparatively, 1.0% of Cleveland BioLabs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend NOVN or CBLI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novan	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cleveland BioLabs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Does the media prefer NOVN or CBLI?

In the previous week, Novan had 1 more articles in the media than Cleveland BioLabs. MarketBeat recorded 1 mentions for Novan and 0 mentions for Cleveland BioLabs. Cleveland BioLabs' average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.

Company	Overall Sentiment
Novan	Neutral
Cleveland BioLabs	Neutral

Does the MarketBeat Community favor NOVN or CBLI?

Cleveland BioLabs received 37 more outperform votes than Novan when rated by MarketBeat users. Likewise, 60.66% of users gave Cleveland BioLabs an outperform vote while only 56.50% of users gave Novan an outperform vote.

Company	Underperform	Outperform
Novan	Outperform Votes 239 56.50%	Underperform Votes 184 43.50%
Cleveland BioLabs	Outperform Votes 276 60.66%	Underperform Votes 179 39.34%

Which has preferable earnings & valuation, NOVN or CBLI?

Cleveland BioLabs has lower revenue, but higher earnings than Novan.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novan	$24.71M	0.00	-$31.31M	-$1.32	0.00
Cleveland BioLabs	$260K	0.04	-$2.40M	N/A	N/A

Which has more risk and volatility, NOVN or CBLI?

Novan has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Cleveland BioLabs has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Summary

Cleveland BioLabs beats Novan on 8 of the 12 factors compared between the two stocks.